GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
415.54
+3.63 (0.88%)
At close: Sep 18, 2025
0.88%
Market Cap132.34B
Revenue (ttm)62.62B
Net Income (ttm)9.08B
Shares Out318.47M
EPS (ttm)28.50
PE Ratio14.58
Forward PEn/a
Dividend10.00 (2.43%)
Ex-Dividend DateSep 5, 2025
Volume200,914
Average Volume499,840
Open413.00
Previous Close411.91
Day's Range410.81 - 416.00
52-Week Range169.00 - 481.00
Beta0.37
RSI54.25
Earnings DateAug 22, 2025

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,700
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2024, GlaxoSmithKline Pakistan's revenue was 61.19 billion, an increase of 23.21% compared to the previous year's 49.66 billion. Earnings were 6.54 billion, an increase of 1124.09%.

Financial Statements

News

There is no news available yet.